Galux key facts
as of Oct 2026- Developer of molecular design technology designed to develop novel drugs against attractive targets.
- Galux is valued at approximately $67.8M as of Oct 2026 (last reported valuation).
- It has raised $32.4M; the latest was Later Stage VC ($28.8M) in Feb 2026.
- Notable investors include Korea Development Bank, InterVest, KDB Capital, DAYLI Partners, NH Investment & Securities — 20 tracked in total.
- Status: Privately Held (backing).
Galux's last reported valuation, Oct 2022. Nothing priced has surfaced since.
- ·The complete investor list: 20 names
- ·Watch Galux: the Monday email on marks, rounds and moves
Galux funding rounds
No funding rounds for Galux are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Galux
20+Galux valuation
Galux's last reported valuation was $67.8 million in Oct 2022. No priced round, secondary trade or fund mark has surfaced since.
Galux investors
20 investors are on record for Galux, including Korea Development Bank, InterVest, KDB Capital and DAYLI Partners. By type, the record holds 5 venture capital firms and 1 fund of funds.
About Galux
Developer of molecular design technology designed to develop novel drugs against attractive targets. The company's technology leverages the integration of artificial intelligence, physics, and chemistry to design various biomolecules, from small molecules to peptides of several amino acids and larger proteins, helping health professionals treat incurable and rare diseases.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2020
- Employees
- 36
- Website
- galux.co.kr/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.